The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 21, 2017

Filed:

Nov. 27, 2009
Applicants:

Rafi Ahmed, Atlanta, GA (US);

Rama Amara, Decatur, GA (US);

Vijayakumar Velu, Tucker, GA (US);

Kehmia Titanji, Atlanta, GA (US);

Gordon Freeman, Brookline, MA (US);

Inventors:

Rafi Ahmed, Atlanta, GA (US);

Rama Amara, Decatur, GA (US);

Vijayakumar Velu, Tucker, GA (US);

Kehmia Titanji, Atlanta, GA (US);

Gordon Freeman, Brookline, MA (US);

Assignees:

Emory University, Atlanta, GA (US);

Dana-Farber Cancer Institute, Inc., Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/02 (2006.01); C07K 16/28 (2006.01); A61K 31/7105 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 31/7105 (2013.01); A61K 39/39 (2013.01); A61K 39/39541 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); G01N 33/5052 (2013.01); G01N 33/56966 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/55516 (2013.01); C07K 2317/24 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); G01N 2333/52 (2013.01);
Abstract

PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist. Methods are also disclosed for determining the efficacy of a PD-1 antagonist in a subject administered the PD-1 antagonist. In some embodiments, these methods include measuring proliferation of memory B cells in a sample from a subject administered the PD-1 antagonist.


Find Patent Forward Citations

Loading…